An integrated tumor, immune and microbiome atlas of colon cancer
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
The lack of multi-omics cancer datasets with extensive follow-up information hinders the identification of accurate biomarkers of clinical outcome. In this cohort study, we performed comprehensive genomic analyses on fresh-frozen samples from 348 patients affected by primary colon cancer, encompassing RNA, whole-exome, deep T cell receptor and 16S bacterial rRNA gene sequencing on tumor and matched healthy colon tissue, complemented with tumor whole-genome sequencing for further microbiome characterization. A type 1 helper T cell, cytotoxic, gene expression signature, called Immunologic Constant of Rejection, captured the presence of clonally expanded, tumor-enriched T cell clones and outperformed conventional prognostic molecular biomarkers, such as the consensus molecular subtype and the microsatellite instability classifications. Quantification of genetic immunoediting, defined as a lower number of neoantigens than expected, further refined its prognostic value. We identified a microbiome signature, driven by Ruminococcus bromii, associated with a favorable outcome. By combining microbiome signature and Immunologic Constant of Rejection, we developed and validated a composite score (mICRoScore), which identifies a group of patients with excellent survival probability. The publicly available multi-omics dataset provides a resource for better understanding colon cancer biology that could facilitate the discovery of personalized therapeutic approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., et al. (2020) · Nature · doi:10.1038/s41586-020-2095-1 · Cited by 989
RetractedComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Self-citationGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Reagent and laboratory contamination can critically impact sequence-based microbiome analyses
Salter, S. J., Cox, M. J., Turek, E. M., Calus, S. T., Cookson, W. O., Moffatt, M. F., Turner, P., Parkhill, J., Loman, N. J., & Walker, A. W. (2014) · BMC Biology · doi:10.1186/s12915-014-0087-z · Cited by 3,463
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
Comprehensive Characterization of Cancer Driver Genes and Mutations
Bailey, M. H., Tokheim, C., Porta-Pardo, E., Sengupta, S., Bertrand, D., Weerasinghe, A., Colaprico, A., Wendl, M. C., Kim, J., Reardon, B., et al. (2018) · Cell · doi:10.1016/j.cell.2018.02.060 · Cited by 2,256
Cited by
Piccinno (2025) · doi:10.1038/s41591-025-03693-9 · Cited by 133
“Our study also demonstrates that the in situ primary tumor is linked to the usual stool CRC microbiome signature, independent of the sidedness, confirming previous evidence that the primary tumor harbors usual CRC biomarkers, such as F. nucleatum 47 .”
Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03235-9 · Cited by 82
Borràs, D. M., Verbandt, S., Ausserhofer, M., Sturm, G., Lim, J., Verge, G. A., Vanmeerbeek, I., Laureano, R. S., Govaerts, J., Sprooten, J., et al. (2023) · Cell Discovery · doi:10.1038/s41421-023-00605-4 · Cited by 67
MS-20 enhances the gut microbiota-associated antitumor effects of anti-PD1 antibody
Lee, P.-J., Hung, C.-M., Yang, A.-J., Hou, C.-Y., Chou, H.-W., Chang, Y.-C., Chu, W.-C., Huang, W.-Y., Kuo, W.-C., Yang, C.-C., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2380061 · Cited by 33
“29 For instance, Clostridiales is positively correlated with increased intratumour CD8 + T cells and granzyme B expression in individuals with melanoma.”
BackgroundValles-Colomer, M., Manghi, P., Cumbo, F., Masetti, G., Armanini, F., Asnicar, F., Blanco-Miguez, A., Pinto, F., Punčochář, M., Garaventa, A., et al. (2024) · eBioMedicine · doi:10.1016/j.ebiom.2023.104917 · Cited by 14
“12,60,61 Importantly, while confounding can never be fully discarded in micro-biome studies, in our study design we selected patients at disease onset (i.e. prior to starting any medication or treatment that could potentially modify the composition of the gut microbiome) and we carefully balanced…”
Background
Metadata
- Authors
- Roelands, J., Kuppen, P. J. K., Ahmed, E. I., Mall, R., Masoodi, T., Singh, P., Monaco, G., Raynaud, C., de Miranda, N. F. C. C., Ferraro, L., Carneiro-Lobo, T. C., Syed, N., Rawat, A., Awad, A., Decock, J., Mifsud, W., Miller, L. D., Sherif, S., Mohamed, M. G., Rinchai, D., Van den Eynde, M., Sayaman, R. W., Ziv, E., Bertucci, F., Petkar, M. A., Lorenz, S., Mathew, L. S., Wang, K., Murugesan, S., Chaussabel, D., Vahrmeijer, A. L., Wang, E., Ceccarelli, A., Fakhro, K. A., Zoppoli, G., Ballestrero, A., Tollenaar, R. A. E. M., Marincola, F. M., Galon, J., Khodor, S. A., Ceccarelli, M., Hendrickx, W., & Bedognetti, D.
- Venue
- Nature Medicine
- Published
- 2023-05
- Volume
- 29
- Issue
- 5
- Pages
- 1273-1286
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4377019784
- Cited by
- 213
- References
- 30
- FWCI
- 22.16
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An integrated tumor, immune and microbiome atlas of colon cancer. https://app.cochat.ai/papers/10.1038/s41591-023-02324-5
- The paper
- Roelands, J., Kuppen, P. J. K., Ahmed, E. I., Mall, R., Masoodi, T., Singh, P., Monaco, G., Raynaud, C., de Miranda, N. F. C. C., Ferraro, L., Carneiro-Lobo, T. C., Syed, N., Rawat, A., Awad, A., Decock, J., Mifsud, W., Miller, L. D., Sherif, S., Mohamed, M. G., . . . Bedognetti, D. (2023). An integrated tumor, immune and microbiome atlas of colon cancer. Nature Medicine. https://doi.org/10.1038/s41591-023-02324-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.